



Edition: BP 2025 (Ph. Eur. 11.6 update)

Dicycloverine Oral Solution

[General Notices](#)

Action and use

Anticholinergic.

DEFINITION

Dicycloverine Oral Solution is a solution of Dicycloverine Hydrochloride in a suitable flavoured vehicle.

The oral solution complies with the requirements stated under Oral Liquids and with the following requirements.

Content of dicycloverine hydrochloride, $C_{19}H_{35}NO_2 \cdot HCl$

90.0 to 110.0% of the stated amount.

IDENTIFICATION

- A. To a volume containing 0.1 g of dicycloverine hydrochloride add 10 mL of [water](#) and 1 mL of [hydrochloric acid](#), shake with 30 mL of [ether](#) and allow to separate. Extract the aqueous layer with 30 mL of [chloroform](#), wash the extract with two 10 mL quantities of [water](#) and filter the chloroform solution through [anhydrous sodium sulfate](#). Evaporate the filtrate to dryness, recrystallise the residue from hot [acetone](#) and dry the precipitate at 105° for 30 minutes. The [infrared absorption spectrum](#) of the residue, [Appendix II A](#), is concordant with the *reference spectrum* of dicycloverine hydrochloride ([RS 098](#)).
- B. Acidify the oral solution with 2M [nitric acid](#) and add [silver nitrate solution](#). A white precipitate is produced.

TESTS

Related substances

Carry out the method for [thin-layer chromatography](#), [Appendix III A](#), using the following solutions.

- (1) Add 10 mL of [water](#) and 1 mL of [hydrochloric acid](#) to a volume containing 0.1 g of dicycloverine hydrochloride, shake with 30 mL of [ether](#) and allow to separate. Extract the aqueous layer with 30 mL of [dichloromethane](#), wash the extract with two 10 mL quantities of [water](#), shake with [anhydrous sodium sulfate](#), filter (Whatman 1PS paper is suitable), evaporate the filtrate to dryness and dissolve the residue in 4 mL of [dichloromethane](#).
- (2) Dilute 1 volume of solution (1) to 500 volumes with [dichloromethane](#).
- (3) 0.1% w/v of each of [dicycloverine hydrochloride BPCRS](#) and [tropicamide BPCRS](#) in [methanol](#).

CHROMATOGRAPHIC CONDITIONS

- (a) Use as the coating [silica gel](#). *G*
- (b) Use the mobile phase as described below.
- (c) Apply 10 µL of each solution.
- (d) Develop the plate to 15 cm.
- (e) After removal of the plate, dry it in a current of warm air and spray with [dilute potassium iodobismuthate solution](#).

MOBILE PHASE

5 volumes of 13.5M [ammonia](#), 10 volumes of [ethyl acetate](#), 10 volumes of [water](#) and 75 volumes of [propan-1-ol](#).

SYSTEM SUITABILITY

The test is not valid unless the chromatogram obtained with solution (3) shows two clearly separated spots.

LIMITS

In the chromatogram obtained with solution (1):

any [secondary spot](#) is not more intense than the spot in the chromatogram obtained with solution (2) (0.2%).

Disregard any spot remaining on the line of application.

ASSAY

To a weighed quantity containing 5 mg of dicycloverine hydrochloride add 5 mL of [sulfuric acid](#) (10%) and 2 mL of 0.02M [potassium permanganate](#), mix, allow to stand, add 20 mL of [water](#) and 20 mL of [chloroform](#) to the decolourised solution and titrate with 0.001M [sodium dodecyl sulfate VS](#) using 1 mL of [dimethyl yellow solution](#) as indicator. Each mL of 0.001M [sodium dodecyl sulfate VS](#) is equivalent to 0.3460 mg of $C_{19}H_{35}NO_2 \cdot HCl$. Determine the [weight per mL](#) of the oral solution, [Appendix V G](#), and calculate the content of $C_{19}H_{35}NO_2 \cdot HCl$, weight in volume.

STORAGE

Dicycloverine Oral Solution should be protected from light.